Valeo Pharma Inc. (VPH.C) announced today that it has successfully entered into a Product Listing Agreement (PLA) with the Quebec Minister of Health. According to this agreement, the Company…
Reimbursement
Valeo Pharma’s (VPH.C) low molecular weight heparin (LMWH) drug, Redesca and Redesca HP, is now eligible for public reimbursement in seven provinces and territories across Canada, as well as…